Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idar...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Siberian Branch Publishing House
2020-05-01
|
| Series: | Сибирский научный медицинский журнал |
| Subjects: | |
| Online Access: | https://sibmed.elpub.ru/jour/article/view/374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318852326850560 |
|---|---|
| author | A.-S. O. Bady S. S. Fedorova D. A. Yakhontov T. I. Pospelova |
| author_facet | A.-S. O. Bady S. S. Fedorova D. A. Yakhontov T. I. Pospelova |
| author_sort | A.-S. O. Bady |
| collection | DOAJ |
| description | Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idarubicyn, mitoxantron) which usually used at medical scheme because of wide spectrum of action and high effectiveness prescription. Risk of cardiotoxicity formation and existing diseases progression increases according to drug dose, patient’s age, cardiovascular risk factors presence and cardiovascular diseases history. Material and methods. 88 patients with established non-Hodgkin’s lymphoma diagnosis were examined in order to assess cardiovascular system state and pathology nature – 33 patients before chemotherapy and 55 patients in the long-term follow-up period (one year after the start of chemotherapy). Results. It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) – the main biomarker of myocardial dysfunction has been revealed by instrumental research. |
| format | Article |
| id | doaj-art-51982991cf8e43d0b1e3dc509cf53ff2 |
| institution | Kabale University |
| issn | 2410-2512 2410-2520 |
| language | Russian |
| publishDate | 2020-05-01 |
| publisher | Russian Academy of Sciences, Siberian Branch Publishing House |
| record_format | Article |
| series | Сибирский научный медицинский журнал |
| spelling | doaj-art-51982991cf8e43d0b1e3dc509cf53ff22025-08-20T03:50:43ZrusRussian Academy of Sciences, Siberian Branch Publishing HouseСибирский научный медицинский журнал2410-25122410-25202020-05-01402737910.15372/SSMJ20200210258Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapyA.-S. O. Bady0S. S. Fedorova1D. A. Yakhontov2T. I. Pospelova3Novosibirsk State Medical University of Minzdrav of RussiaNovosibirsk State Medical University of Minzdrav of RussiaNovosibirsk State Medical University of Minzdrav of RussiaNovosibirsk State Medical University of Minzdrav of RussiaChemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idarubicyn, mitoxantron) which usually used at medical scheme because of wide spectrum of action and high effectiveness prescription. Risk of cardiotoxicity formation and existing diseases progression increases according to drug dose, patient’s age, cardiovascular risk factors presence and cardiovascular diseases history. Material and methods. 88 patients with established non-Hodgkin’s lymphoma diagnosis were examined in order to assess cardiovascular system state and pathology nature – 33 patients before chemotherapy and 55 patients in the long-term follow-up period (one year after the start of chemotherapy). Results. It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) – the main biomarker of myocardial dysfunction has been revealed by instrumental research.https://sibmed.elpub.ru/jour/article/view/374cardiotoxicityanthracyclinesnon-hodgkin’s lymphomachemotherapydoxorubicinntprobnpcardiomyopathy |
| spellingShingle | A.-S. O. Bady S. S. Fedorova D. A. Yakhontov T. I. Pospelova Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy Сибирский научный медицинский журнал cardiotoxicity anthracyclines non-hodgkin’s lymphoma chemotherapy doxorubicin ntprobnp cardiomyopathy |
| title | Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy |
| title_full | Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy |
| title_fullStr | Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy |
| title_full_unstemmed | Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy |
| title_short | Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy |
| title_sort | cardiovascular system state changes in non hodgkin s lymphoma patients during chemotherapy |
| topic | cardiotoxicity anthracyclines non-hodgkin’s lymphoma chemotherapy doxorubicin ntprobnp cardiomyopathy |
| url | https://sibmed.elpub.ru/jour/article/view/374 |
| work_keys_str_mv | AT asobady cardiovascularsystemstatechangesinnonhodgkinslymphomapatientsduringchemotherapy AT ssfedorova cardiovascularsystemstatechangesinnonhodgkinslymphomapatientsduringchemotherapy AT dayakhontov cardiovascularsystemstatechangesinnonhodgkinslymphomapatientsduringchemotherapy AT tipospelova cardiovascularsystemstatechangesinnonhodgkinslymphomapatientsduringchemotherapy |